Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma
Antineoplastic Combined Chemotherapy Protocols
In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.).